Newtyn Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Newtyn Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,810,000	Closed	-$5.5M	–	35
2024 Q4	$5.5M	Buy	+1,810,000	New	+$7.88M	0.96%	26

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Newtyn Management's RVNC Position: Q1 2025 in Review

Newtyn Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,810,000 shares — an estimated $5.5M sold.

Newtyn Management first reported a position in RVNC in Q4 2024 and held it in 1 quarter. The position peaked at $5.5M in Q4 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Newtyn Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Newtyn Management sold 1,810,000 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $5.5M.
Newtyn Management first reported a position in Revance Therapeutics, Inc. in Q4 2024 and held it in 1 quarter.
Newtyn Management's Revance Therapeutics, Inc. position peaked at $5.5M in Q4 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Newtyn Management's 13F filing for Q1 2025, filed 15 May 2025.